Drug Watch
Compounds in Development for Chronic Hepatitis B
Updated Dec. 3, 2020
FAMILY/DRUG NAME |
MECHANISM |
COMPANY |
WEBSITE |
|
|||||||||||||||
|
Interferons: Mimic infection-fighting immune substances naturally produced in the body
|
|||||||||||||||||||
| Intron A (Interferon alfa 2b) | Immunomodulator | Merck, USA | merck.com | Approved 1991 | |||||||||||||||
|
Pegasys (Peginterferon alfa 2a) |
Immunomodulator |
Genentech, USA |
Approved 2005 |
||||||||||||||||
|
Nucleos(t)ide Analogues: Interfer with viral DNA polymerase used for HBV replication |
|||||||||||||||||||
|
Epivir (Lamivudine) *Generics available |
Inhibits viral DNA polymerase | GlaxoSmithKline (GSK) | gsk.com | Approved 1998 | |||||||||||||||
| Hepsera (Adefovir dipivoxil) *Generics available | Inhibits viral DNA polymerase | Gilead Sciences, USA | gilead.com | Approved 2002 | |||||||||||||||
|
Baraclude (Entecavir) *Generics available |
Inhibits viral DNA polymerase | Bristol-Myers Squibb, USA | bms.com | Approved 2005 | |||||||||||||||
| Tyzeka (Telbivudine) *Generics available | Inhibits viral DNA polymerase | Novartis, USA | novartis.com | Approved 2006 | |||||||||||||||
| Viread (Tenofovir) *Generics available | Inhibits viral DNA polymerase | Gilead Sciences | gilead.com | Approved 2008 | |||||||||||||||
| Vemlidy (TAF or tenofovir alfenamide) | Prodrug of Tenofovir | Gilead Sciences | gilead.com | Approved 2016 | |||||||||||||||
|
Levovir (Cledvudine) |
Inhibits viral DNA polymerase | Bukwang, S. Korea | bukwang.co.kr | Approved 2006 in S. Korea | |||||||||||||||
|
Besivo (formerly ANA 380/LB80380) |
Inhibits viral DNA polymerase | Ildong Pharma, S. Korea | ildong.com | Approved 2017 in S. Korea | |||||||||||||||
|
Zadaxin |
Immunomodulator | SciClone, USA | sciclone.com | Approved outside USA | |||||||||||||||
|
ATI-2173 |
Inhibits HBV polymerase |
Antios Therapeutics, USA |
Phase I |
||||||||||||||||
|
Direct Acting Antivirals: Targets the virus and interferes in the HBV replication process |
|||||||||||||||||||
|
Silencing RNA’s (siRNAs): Interferes and destroys viral RNA |
|||||||||||||||||||
|
VIR-2218 |
RNAi gene silencer |
Vir Biotech, USA |
Phase II |
||||||||||||||||
|
RG6346 (DCR HBVS) |
RNAi gene silencer |
Roche, Switzerland, with Dicerna |
Phase I/II |
||||||||||||||||
|
JNJ-3989 (ARO-HBV) |
RNAi gene silencer |
J&J with Arrowhead, USA |
Phase II | ||||||||||||||||
|
AB-729 |
RNAi gene silencer |
Arbutus Biopharma, USA |
Phase I | ||||||||||||||||
|
BB-103 |
RNAi gene silencer |
Benitec, Australia |
Preclinical |
||||||||||||||||
|
ALG-125097 |
RNAi gene silencer |
Aligos Therapeutics, USA |
Preclinical |
||||||||||||||||
|
Entry Inhibitors: Interferes with HBV getting into liver cells |
|||||||||||||||||||
|
Hepcludex (Bulevirtide formerly Myrcludex B) |
Entry inhibitor |
MYR GmbH, Germany |
Phase II |
||||||||||||||||
|
Capsid or Core Inhibitors: Interferes with the viral DNA protein shield |
|||||||||||||||||||
|
Vebicorvir (ABI-HB0731) |
Capsid inhibitor |
Assembly Biosciences, USA |
|||||||||||||||||
|
Morphothiadin |
Capsid inhibitor |
HEC Pharma, PR China |
pharm.hec.cn/en/ | Phase II | |||||||||||||||
|
JNJ 56136379 |
Capsid inhibitor |
Janssen, Ireland |
|||||||||||||||||
|
ABI-H0731 |
Capsid inhibitor |
Assembly Biosciences, USA |
Phase II |
||||||||||||||||
|
ABI-H2158 |
Capsid inhibitor |
Assembly Biosciences, USA |
Phase II | ||||||||||||||||
|
RG7907 |
Capsid inhibitor |
Roche, Switzerland |
Phase I | ||||||||||||||||
|
QL-007 |
Capsid inhibitor |
Qilu, PR China |
Phase I | ||||||||||||||||
|
EDP-514 |
Capsid inhibitor |
Enanta Pharma, USA |
Phase I | ||||||||||||||||
|
ABI-H3733 |
Capsid inhibitor |
Assembly Biosciences, USA |
Phase I | ||||||||||||||||
|
ZM-H1505R |
Capsid inhibitor |
ZhiMeng Biopharma, PR China |
Phase I | ||||||||||||||||
|
ALG-000184 |
Capsid inhibitor |
Aligos Therapeutics, USA |
Phase I | ||||||||||||||||
|
GLP-26 |
Capsid inhibitor |
Emory University, USA |
Preclinical | ||||||||||||||||
|
AB-836 |
Capsid inhibitor |
Arbutus, USA |
Preclinical | ||||||||||||||||
|
HBsAg Inhibitors: Interferes with production of HBV surface antigen (sAg) |
|||||||||||||||||||
|
REP 2139 |
sAg inhibitor |
Replicor, Canada |
Phase II |
||||||||||||||||
|
REP 2165 |
sAg inhibitor |
Replicor, Canada |
Phase II |
||||||||||||||||
|
ALG-10133 |
sAg inhibitor |
Aligos Therapeutics, USA |
Phase I | ||||||||||||||||
|
Antisense Molecules: Binds to the viral mRNA to prevent it from turning into viral protein |
|||||||||||||||||||
|
IONIS-HBVRx (GSK 3228836) |
Prevent viral protein production |
Ionis with GSK, USA |
Phase II |
||||||||||||||||
|
ALG-020572 |
Prevent viral protein production |
Aligos Therapeutics, USA |
Preclinical | ||||||||||||||||
|
|||||||||||||||||||
|
Immunologicals: Targets the human immune system to attack the HBV virus |
|||||||||||||||||||
|
Therapeutic Vaccine Technology used to stimulate the immune system as a treatment |
|||||||||||||||||||
|
NASVAC |
Therapeutic vaccine |
CIGB, Cuba |
cigb.edu.cu/sobre-cigb/ | Phase III | |||||||||||||||
|
GS-4774 |
Therapeutic vaccine |
Gobelmmune with Gilead, USA |
globeimmune.com |
Phase II |
|||||||||||||||
|
HepTcell |
Therapeutic vaccine |
Altimmune, USA |
Phase II |
||||||||||||||||
|
AIC 649 |
Therapeutic vaccine |
AiCuris, Germany |
Phase I |
||||||||||||||||
|
HB-110 |
Therapeutic vaccine |
Ichor Medical with Genexine, USA |
Phase I |
||||||||||||||||
|
VTP-300 |
Therapeutic vaccine |
Vaccitech, USA |
Phase I |
||||||||||||||||
|
JNJ 64300535 |
Therapeutic vaccine |
Janssen, Ireland |
Phase I |
||||||||||||||||
|
VBI-2601 |
Therapeutic vaccine |
VBI Vaccines, USA |
vbivaccines.com | Phase I | |||||||||||||||
|
Chimigen HBV |
Therapeutic vaccine |
Akshaya, Canada |
akshayabio.com | Preclinical | |||||||||||||||
|
CARG-201 |
Therapeutic vaccine |
CaroGen, USA |
carogencorp.com | Preclinical | |||||||||||||||
|
HBV |
Therapeutic vaccine |
HOOKIPA Pharma, Austria, with Gilead |
hookipapharma.com | Preclinical | |||||||||||||||
|
TherVacB |
Therapeutic vaccine |
Helmholtz Zentrum Muenchen, Germany |
dzif.de/en/hepatitis | Preclinical | |||||||||||||||
|
Toll Receptors: Compounds that activate the innate immune system |
|||||||||||||||||||
|
Selgantolimod (GS9688) |
TLR-8 agonist |
Gilead Sciences, USA |
Phase II |
||||||||||||||||
|
RG7854 |
TLR-7 agonist |
Roche, Switzerland |
Phase I | ||||||||||||||||
|
SBT 8230 |
TLR-8 agonist |
Silverback Therapeutics, USA |
silverbacktx.com | Preclinical | |||||||||||||||
|
Monoclonal Antibodies: Neutralize or bind the HBV proteins to reduce infection |
|||||||||||||||||||
|
GC1102 |
Monoclonal antibody | Green Cross, South Korea | globalgreencross.com | Phase II | |||||||||||||||
|
Vir-3434 |
Monoclonal antibody | Vir Biotech, USA | vir.bio | Phase I | |||||||||||||||
|
Checkpoint Inhibitors: Stimulate exhausted T-cell recognition of HBV-Infected cells |
|||||||||||||||||||
|
ASC22 |
PDL1 inhibitor | Ascletis Pharma, PR China | ascletis.com | Phase II | |||||||||||||||
|
GS 4224 |
PDL1 inhibitor | Gilead, USA | gilead.com | Preclinical | |||||||||||||||
|
Other Immunologicals |
|||||||||||||||||||
|
IMC-I109V |
T-cell Receptor | Immunocore | immunocore.com | Phase II | |||||||||||||||
|
LTCR-H2-1 |
T Cell. immunotherapy | Lion TCR, Singapore | liontcr.com | Preclinical | |||||||||||||||
|
Additional HBV Drugs Under Investigation |
|||||||||||||||||||
|
EYP001 |
FXR agonist | Enyo Pharma, France | enyopharma.com | Phase I | |||||||||||||||
|
APG-1387 |
Apoptosis inducer | Ascentage, PR China | ascentagepharma.com | Phase II | |||||||||||||||
|
HBV |
MicroRNA | Regulus, USA | regulusrx.com | Preclinical | |||||||||||||||
|
ENOB-HB-01 |
Gene modified cell therapy | Enochian Bio, USA | enochianbio.com | Preclinical | |||||||||||||||
|
GV1001 |
"Novel peptide" | GemVax & KAEL, South Korea | gemvax.com | Preclinical | |||||||||||||||
|
CP101 |
Oral microbiotic | Finch Therapeutics, USA | finchtherapeutics.com | Preclinical | |||||||||||||||
|
Hepatitis Delta Virus (HDV)- A virus that co-infects people already infected with HBV |
|||||||||||||||||||
|
Hepcludex (Bulevirtide formerly Myrcludex B) |
Entry inhibitor |
MYR-GmbH, Germany |
Approved in Europe Aug. 14, 2020 |
||||||||||||||||
|
Lonafarnib |
Prenylation inhibitor |
Eiger Biopharma, USA |
Orphan drug |
||||||||||||||||
|
REP 2139 |
HBsAg inhibitor |
Replicor, Canada |
Phase II |
||||||||||||||||
|
Ezetimibe |
NTCP inhibitor |
Ziauddin University Hospital, Pakistan |
Phase II |
||||||||||||||||
|
GI-18000 |
Immune Response Stimulator |
GlobeImmune, USA |
Preclinical |
||||||||||||||||